

EnzymeRx

Changing the Treatment
Paradigm for Refractory Gout

17 Arcadian Avenue, Suite 104
Paramus, NJ 07652
Phone: (201) 843-4424
Fax: (201) 458-9741
www.enzymerx.com

EnzymeRx Announces Management Appointments in the areas of Biologics Manufacturing and Pre-Clinical R&D

Dr. Elizabeth John and Dr. John (Zhihua) Zhang Assume Leadership Positions, furthering the development of uricase-PEG 20

March 19, 2009


Paramus, NJ. [EnzymeRx](http://www.enzymerx.com) today announced two significant additions to its management team.

Joining EnzymeRx as Vice President, Manufacturing is Elizabeth John, Ph.D. Elizabeth has most recently served as Head of Research and Development at Centegen, a biotechnology start-up. She brings 17 years of experience in the manufacture of biologics and the regulation of biologics manufacturing to EnzymeRx, and in her career has contributed to multiple INDs, managed drug development programs, and has interacted closely with the FDA and foreign regulatory agencies. Elizabeth received her Ph.D. in Chemistry from Rutgers University and completed post-doctoral training in radiopharmaceutical chemistry at Purdue University. She also received an M.S. in Chemistry from the Indian Institute of Technology in Madras.

EnzymeRx also welcomes John (Zhihua) Zhang, M.D., Ph.D. as our Vice President, Preclinical Research and Development. John most recently served as Director, Preclinical Pharmacology and Toxicology at Pharmacopeia until its acquisition by Ligand Pharmaceuticals. John was previously Associate Director and Department Head of Toxicology and Drug Metabolism and Pharmacokinetics at Enzon Pharmaceuticals, and has additionally managed toxicology programs for several projects at Hoffmann-La Roche and Abbott Laboratories. John obtained a Ph.D. in toxicology from Rutgers University and performed post-doctoral training in National Cancer Institute of NIH. John also holds an M.S. in public health from UCLA and an M.D. from Guangxi Medical University in China.

Tony Fiorino, President and Chief Executive Officer of EnzymeRx, commented on these important additions. “We are excited to welcome these two new members of the EnzymeRx team. Elizabeth brings incredible depth of experience in biologics manufacturing of to us, and has assumed control of our entire program. John has, in addition to his toxicology expertise, an impressive breadth of experience across preclinical research and development, and has worked on a number of pegylated compounds and other biologics. Both have already made important contributions to EnzymeRx and will help us accelerate the development of [uricase-PEG 20](#).”

EnzymeRx is also pleased to provide an update on its progress in moving uricase-PEG 20 back into the clinic. The company has held meetings with the FDA regarding the development path in



EnzymeRx

Changing the Treatment
Paradigm for Refractory Gout

17 Arcadian Avenue, Suite 104
Paramus, NJ 07652
Phone: (201) 843-4424
Fax: (201) 458-9741
www.enzymerx.com

both gout and tumor lysis syndrome, and is currently finishing the preclinical toxicology studies and additional analytical work requested by the Agency. EnzymeRx expects to continue the clinical development of uricase-PEG 20 later this year, after these studies are completed and the results filed with the FDA.

About EnzymeRx

EnzymeRx, LLC is a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role. Our patented formulation of pegylated uricase is designed to have a long half life as well as reduced immunogenicity. For more information about EnzymeRx, uricase or gout, please visit www.enzymerx.com.

Contact

EnzymeRx, LLC
Tony Fiorino, MD, PhD
(201) 843-4424
info@enzymerx.com